ClinicalTrials.gov record
Active, not recruiting Not applicable Interventional Results available

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

ClinicalTrials.gov ID: NCT02226276

Public ClinicalTrials.gov record NCT02226276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine

Study identification

NCT ID
NCT02226276
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Not applicable
Lead sponsor
City of Hope Medical Center
Other
Enrollment
10 participants

Conditions and interventions

Interventions

  • ado-trastuzumab emtansine Biological
  • computed tomography Procedure
  • copper Cu 64-DOTA-trastuzumab Radiation
  • fludeoxyglucose F 18 Radiation
  • laboratory biomarker analysis Other
  • positron emission tomography Procedure
  • trastuzumab Biological

Biological · Procedure · Radiation + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 6, 2015
Primary completion
Dec 6, 2021
Completion
Sep 28, 2026
Last update posted
Feb 12, 2026

2015 – 2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02226276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02226276 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →